Candel Therapeutics, Inc. (CADL)
NASDAQ:CADL
Want to see CADL full AI Analyst Report?
CADL Stock Chart & Stats
$6.37
$0.00(0.00%)
At close: 4:00 PM EST
$6.37
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$4.35 - $9.57
Previous CloseN/A
Volume524.53K
Average Volume (3M)2.28M
Market Cap
$717.32M
Enterprise Value$245.62M
Total Cash (Recent Filing)$194.83M
Total Debt (Recent Filing)$1.80M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Aug 19, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding73,270,240
10 Day Avg. Volume2,306,496
30 Day Avg. Volume2,278,531
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)5.76
Price to Sales (P/S)0.00
P/FCF Ratio-7.69
Enterprise Value/Market Cap0.34
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.88
Forecast
1Y Price Target
$20.60Price Target Upside223.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.94
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA materially stronger equity base and very low leverage give Candel financial flexibility to fund clinical programs and operate over coming months without immediate debt pressure. This reduces short-term liquidation risk and supports strategic options like partnerships or milestone-driven financings.
Progressing Phase 3 DataExtended follow-up from a randomized Phase 3 trial strengthens the clinical evidence for the lead program, de-risking development and improving the company’s ability to attract partners or regulatory support. Durable clinical signals materially affect long-term commercialization prospects.
Governance And Leadership ContinuityBoard continuity and an established independent auditor signal stable governance and financial oversight. Consistent oversight from experienced directors supports disciplined clinical strategy execution and increases credibility with potential collaborators and investors.
Bears Say
Pre-revenue ModelWith no product revenue, the business must rely on external financing or partnership deals to fund operations. This structural lack of recurring cash inflows amplifies dependency on clinical milestones and raises execution risk for sustaining R&D and trials over the medium term.
High Cash BurnSustained negative operating and free cash flow at this magnitude consumes cash reserves rapidly, pressuring runway. Even with improved FCF versus prior year, persistent burn necessitates near-term funding events that can dilute shareholders or force less favorable financing terms.
Negative Returns & Dilution RiskDeeply negative ROE shows capital deployed is not producing returns, reflecting continued losses. That performance, combined with biotech funding norms, implies likely future equity raises and dilution, which can pressure long-term shareholder value absent clear clinical or commercial inflection points.
Candel Therapeutics News
CADL FAQ
What was Candel Therapeutics, Inc.’s price range in the past 12 months?
Candel Therapeutics, Inc. lowest stock price was $4.35 and its highest was $9.57 in the past 12 months.
What is Candel Therapeutics, Inc.’s market cap?
Candel Therapeutics, Inc.’s market cap is $717.32M.
When is Candel Therapeutics, Inc.’s upcoming earnings report date?
Candel Therapeutics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 52 days.
How were Candel Therapeutics, Inc.’s earnings last quarter?
Candel Therapeutics, Inc. released its earnings results on May 14, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.296 by $0.156.
Is Candel Therapeutics, Inc. overvalued?
According to Wall Street analysts Candel Therapeutics, Inc.’s price is currently Undervalued.
Does Candel Therapeutics, Inc. pay dividends?
Candel Therapeutics, Inc. does not currently pay dividends.
What is Candel Therapeutics, Inc.’s EPS estimate?
Candel Therapeutics, Inc.’s EPS estimate is -0.23.
How many shares outstanding does Candel Therapeutics, Inc. have?
Candel Therapeutics, Inc. has 73,270,240 shares outstanding.
What happened to Candel Therapeutics, Inc.’s price movement after its last earnings report?
Candel Therapeutics, Inc. reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.296. Following the earnings report the stock price went down -0.336%.
Which hedge fund is a major shareholder of Candel Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CADL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Candel Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.60 (223.39% Upside)
$20.60 (223.39% Upside)
Blogger Sentiment
Bullish
CADL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 156.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
94.63%
12-Months-Change
Fundamentals
Return on Equity
-60.42%
Trailing 12-Months
Asset Growth
110.54%
Trailing 12-Months
Company Description
Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
CADL Stock 12 Month Forecast
Average Price Target
$20.60
▲(223.39% Upside)
Technical Analysis
Tonix Pharma
―
Quantum-Si
―
Humacyte
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
9.51% Insiders
17.35% Mutual Funds
28.22% Other Institutional Investors
34.66% Public Companies and
Individual Investors